Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Daniel Röshammar"'
Autor:
Emma Eckernäs, Jeroen Koomen, Christopher Timmermann, Robin Carhart‐Harris, Daniel Röshammar, Michael Ashton
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 10, Pp 1398-1410 (2023)
Abstract N,N‐dimethyltryptamine (DMT) is a psychedelic compound that is being studied as a therapeutic option in various psychiatric disorders. Due to its short half‐life, continuous infusion of DMT has been proposed to extend the psychedelic exp
Externí odkaz:
https://doaj.org/article/21b360a33d934211b35cad0efd564dbc
Autor:
Emma Eckernäs, Christopher Timmermann, Robin Carhart‐Harris, Daniel Röshammar, Michael Ashton
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 4, Pp 474-486 (2023)
Abstract N,N‐dimethyltryptamine (DMT) is a psychedelic substance and is being used as a research tool in investigations of the neurobiology behind the human consciousness using different brain imaging techniques. The effects of psychedelics have co
Externí odkaz:
https://doaj.org/article/26a649e9d206424a88560970079a9e46
Autor:
Emma Eckernäs, Christopher Timmermann, Robin Carhart‐Harris, Daniel Röshammar, Michael Ashton
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 12, Pp 2928-2937 (2022)
Abstract N,N‐dimethyltryptamine (DMT) is a psychedelic compound that is believed to have potential as a therapeutic option in several psychiatric disorders. The number of clinical investigations with DMT is increasing. However, very little is known
Externí odkaz:
https://doaj.org/article/c190cda0024e4dd9a568e428507c3983
Autor:
Lesley G. Mitchell, Daniel Röshammar, Fenglei Huang, Manuela Albisetti, Leonardo R. Brandão, Lisa Bomgaars, Elizabeth Chalmers, Jacqueline Halton, Matteo Luciani, David Joseph, Igor Tartakovsky, Savion Gropper, Martina Brueckmann
Publikováno v:
Thrombosis and haemostasis. 122(9)
Background Dabigatran etexilate, a direct oral thrombin inhibitor, is approved to treat venous thromboembolism (VTE) in both adults and children. Objectives This population analysis characterized relationships between dabigatran total plasma concentr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b45305695eff62e547c5b8812ddcd25b
https://pubmed.ncbi.nlm.nih.gov/35909257
https://pubmed.ncbi.nlm.nih.gov/35909257
Autor:
Martina Brueckmann, Lisa Bomgaars, Martin Bergstrand, Lesley G. Mitchell, Moustafa M. A. Ibrahim, Leonardo R. Brandão, Elizabeth Chalmers, Savion Gropper, Fenglei Huang, Jacqueline Halton, Matteo Luciani, Igor Tartakovsky, David Joseph, Manuela Albisetti, Daniel Röshammar
Publikováno v:
Journal of Thrombosis and Haemostasis
Background Dabigatran etexilate (DE), a direct oral thrombin inhibitor, has been evaluated in children with venous thromboembolism (VTE) using oral solution, pellets, or capsules. Objectives This study evaluated DE pharmacokinetics (PK) in children w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e6f28e48321106c7465cc0257b5e3fd
https://doi.org/10.1111/jth.15277
https://doi.org/10.1111/jth.15277
Autor:
Dominick J. Angiolillo, Paul A. Gurbel, Marc P. Bonaca, Anders Himmelmann, Magnus Åstrand, Carl Amilon, Daniel Röshammar, Robert F. Storey, Bengt Hamrén
Publikováno v:
British Journal of Clinical Pharmacology
AIM: To characterize ticagrelor exposure-response relationship for platelet inhibition in patients with stable coronary artery disease (CAD) and a history of myocardial infarction (MI), using non-linear mixed effects modelling and simulation. METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f545785b4f68ef4ff7f3b88cae5df5e
https://doi.org/10.1111/bcp.13812
https://doi.org/10.1111/bcp.13812
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
Population model-based (pharmacometric) approaches are widely used for the analyses of phase IIb clinical trial data to increase the accuracy of the dose selection for phase III clinical trials. On the other hand, if the analysis is based on one sele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::568f24f9aa7cf22f10aae995c074cb6f
http://europepmc.org/articles/PMC5686275
http://europepmc.org/articles/PMC5686275
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 55:416-424
Objective The population pharmacokinetics of ticagrelor and its active metabolite AR-C124910XX were characterized following ticagrelor 60 mg or 90 mg twice daily oral long-term treatment in 4,426 patients with a history of myocardial infarction. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6e2ef9f4fc4db1441fed9e99334b871
https://doi.org/10.5414/cp202748
https://doi.org/10.5414/cp202748
Publikováno v:
Drugs in R&D
Objective The aim of this study was to characterise the population pharmacokinetics of FE 999049, a novel recombinant human follicle-stimulating hormone (FSH), after multiple dosing in healthy women, taking into account endogenous FSH levels and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b91eb35d3ccd56f91fa75d0290f78b7
https://doi.org/10.1007/s40268-016-0126-z
https://doi.org/10.1007/s40268-016-0126-z
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 40:487-496
This work explores the advantages of a model based drug development (MBDD) approach for the design and analysis of antiretroviral phase II trials. Two different study settings were investigated: (1) a 5-arm placebo-controlled parallel group dose-find
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8de1845b5e5079725c8025acfcb85e2
https://doi.org/10.1007/s10928-013-9324-2
https://doi.org/10.1007/s10928-013-9324-2